Related Experiment Video
Updated: Aug 12, 2025

07:50
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
16.0K
Malignancy-associated generalised exfoliative dermatitis: A retrospective study in a single-centre Asian cohort
Valencia Long1, Ellie Ci-En Choi1,2, Chen Zhaojin3
1Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore.
The Australasian Journal of Dermatology
|February 2, 2023
Summary
Malignancy-associated erythroderma (MAE) occurred in 5.4% of patients, with a higher prevalence of 7.8% in those over 65. Systematic screening for malignancy in elderly erythroderma patients is recommended due to potential adverse outcomes from delayed diagnosis.
Area of Science:
- Dermatology
- Oncology
- Epidemiology
Background:
- Erythroderma is a severe inflammatory skin condition affecting over 90% of body surface area.
- Malignancy-associated erythroderma (MAE) is a critical concern requiring prompt diagnosis.
- This study investigates MAE prevalence in a cohort with systematic screening efforts.
Purpose of the Study:
- To determine the prevalence of malignancy in adult erythroderma patients.
- To assess the effectiveness of systematic malignancy screening in this population.
- To compare MAE occurrence with existing literature.
Main Methods:
- Retrospective cohort study of adult erythroderma patients (July 2019 - December 2021).
- Data collection included demographics, clinical findings, investigations, and mortality.
- Focus on patients aged 65 and above offered systematic malignancy screening.
Main Results:
- 74 patients analyzed; median age 73 years.
- Underlying dermatoses (eczema, psoriasis) were the most common causes (63 patients).
- Four patients (5.4%) had associated malignancies; prevalence was 7.8% in patients over 65.
Conclusions:
- Our cohort shows a higher MAE occurrence than previously reported.
- Delayed malignancy evaluation can lead to adverse outcomes.
- Systematic malignancy screening is crucial for high-risk groups like elderly erythroderma patients.

